Olaparib clinical trials
Also written Lynparza, AZD2281 and KU-0059436.
ClinicalTrials.gov finds 505 studies for olaparib. How that becomes 323 here
Every study that search finds has been read, apart from the 2 newest, to see whether and how it gives olaparib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 505Found by its intervention search · See all 505 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 446 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −4
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian CancerNCT05027828 · Not named; PARP inhibitors in generalReport a problem
- Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast CancerNCT06175390 · Not given; tiragolumab and atezolizumab are studiedReport a problem
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy ToxicityNCT07018622 · Listed by mistake as an other name of dapagliflozinReport a problem
- The HER Project: HRD in EGFR-mutated NSCLCNCT07303218 · Mentioned from laboratory work; not givenReport a problem
- −1New since the last reading, not read yet
- 500Give olaparib to participants
- −40Observe patients on it, or give it outside a trial
- −5Use it as a tool: an imaging tracer or a test of drug response
- −2Compare another treatment with it
- −130Give it beside what is tested
- 323Test it: the count on this site
Get an email when these change. Save the olaparib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 Dec 2014 · LYNPARZA · NDA 206162 (FDA, Drugs@FDA)
- European Union
- 16 Dec 2014 · Lynparza · EMEA/H/C/003726 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
321 studies that test it; most in 2019 (37); 1 more planned to start later
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 7 |
| 2008 | 11 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 4 |
| 2012 | 7 |
| 2013 | 12 |
| 2014 | 13 |
| 2015 | 10 |
| 2016 | 22 |
| 2017 | 20 |
| 2018 | 34 |
| 2019 | 37 |
| 2020 | 29 |
| 2021 | 30 |
| 2022 | 29 |
| 2023 | 19 |
| 2024 | 16 |
| 2025 | 7 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 84 · Other 239
AstraZeneca (64) · National Cancer Institute (NCI) (30) · Merck Sharp & Dohme LLC (12) · M.D. Anderson Cancer Center (9) · Memorial Sloan Kettering Cancer Center (8) · The Netherlands Cancer Institute (7) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · University of Washington (4)
Often tested with
Tested in the same studies.
Pembrolizumab (38) · Durvalumab (37) · Palbociclib (13) · Temozolomide (12) · Cediranib (11) · Pertuzumab (10) · Atezolizumab (9) · Carboplatin (9)
Related medicines
As reviewed, each with the page that says it.
- One of PARP inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Olaparib is the comparator. A study of two new drugs counts under both.
- 1Trastuzumab deruxtecan · Prof. Wolfgang Janni · next primary completion Apr 2032
New treatments tested with it · 8 most studied
New when their studies opened, with olaparib beside them; studies of each.
Reaching primary completion within a year · 32, 3 in phase 3
Studies that test olaparib, phase 3 first.
- Apr 2027Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibPhase 3 · AstraZeneca
- May 2027Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Phase 3 · Merck Sharp & Dohme LLC
- Oct 2027Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Phase 3 · Merck Sharp & Dohme LLC
- Nov 2026Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic CancerPhase 2 · Cambridge University Hospitals NHS Foundation Trust
- Dec 2026PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerPhase 2 · Institute of Cancer Research, United Kingdom
- Dec 2026Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic ChangesPhase 2 · National Cancer Institute (NCI)
- Dec 2026Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast CancerPhase 1/2 · Seoul National University Hospital
- Dec 2026Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerPhase 2 · M.D. Anderson Cancer Center
- Dec 2026Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerPhase 1 · National Cancer Institute (NCI)
- Dec 2026Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)Phase 2 · Canadian Cancer Trials Group
Studies
Open first, then newest update. How each study uses olaparib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 323
- Carboplatin or Olaparib for BRcA Deficient Prostate CancerRecruitingPhase 2VA Office of Research and DevelopmentNCT04038502Against carboplatin, in sequence, in prostate cancerWritten as OlaparibReport a problem
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingPhase 3Merck Sharp & Dohme LLCNCT03486873Continued with pembrolizumab in an extension studyWritten as OlaparibReport a problem
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerRecruitingPhase 1National Cancer Institute (NCI)NCT04585958With trastuzumab deruxtecan in HER2-expressing cancersWritten as OlaparibReport a problem
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationRecruitingPhase 2National Cancer Institute (NCI)NCT04858334Against placebo after curative treatmentWritten as OlaparibReport a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377In gene-matched combination armsWritten as OlaparibReport a problem
- Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerRecruitingPhase 3NRG OncologyNCT06580314One or two years, with or without bevacizumabWritten as OlaparibReport a problem
- Pilot Trial for Treatment of Recurrent GlioblastomaEnrolling by invitationEarly Phase 1AHS Cancer Control AlbertaNCT05432518One of five drugs chosen for glioblastomaWritten as OlaparibReport a problem
- Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)RecruitingPhase 1/2National Cancer Institute (NCI)NCT04086485With Lu-177-DOTATATE, its dose foundWritten as OlaparibReport a problem
- Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell TumorsNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07850973With high-dose chemotherapy before stem cell transplantWritten as OlaparibReport a problem
- WIRE - Novel Treatments in Renal Cell CancerRecruitingPhase 2CCTU- Cancer ThemeNCT03741426Alone or with new cediranib in kidney cancerWritten as OlaparibReport a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535One approved drug matched to tumour geneticsWritten as Olaparib (CLOSED TO ENROLLMENT)Report a problem
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690One window arm before pancreatic surgeryWritten as OlaparibReport a problem
- Molecularly Tailored Therapy in Advanced Pancreatic CancerNot yet recruitingPhase 2Herlev HospitalNCT07802418One matched option in tailored pancreatic cancer therapyReport a problem
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001As matched maintenance in a molecular studyWritten as Olaparib (300 mg BID)Report a problem
- Pembrolizumab, Olaparib, and Temozolomide for People With GliomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05188508With pembrolizumab and temozolomide in gliomaWritten as Olaparib and TemozolomideReport a problem
- Pembro With Radiation With or Without OlaparibRecruitingPhase 2Zin W MyintNCT05568550Added to pembrolizumab and radiation in prostate cancerWritten as OlaparibReport a problem
- An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibRecruitingPhase 2University of Colorado, DenverNCT05887609With mirvetuximab as maintenance in ovarian cancerWritten as OlaparibReport a problem
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135One arm of a paediatric precision platformWritten as OlaparibReport a problem
- Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast CancerRecruitingPhase 4Wen-Ming CaoNCT07695259With trastuzumab and pertuzumab before surgery in older womenWritten as olaparib combined with trastuzumab and pertuzumabReport a problem
- Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/PembroRecruitingPhase 2University of Alabama at BirminghamNCT05952453With pembrolizumab as maintenance after neoadjuvant chemotherapyReport a problem
See all 323 studies that test olaparib →
Behind its US label · 8 — the studies the FDA label of LYNPARZA describes
From the Clinical Studies section of LYNPARZA (2025-07), as openFDA has it. A study the site does not hold is left out.
- Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.Active, not recruitingPhase 3AstraZenecaNCT01844986Report a problem
- Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyActive, not recruitingPhase 3AstraZenecaNCT01874353Report a problem
- Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.CompletedPhase 3AstraZenecaNCT02000622Report a problem
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerActive, not recruitingPhase 3AstraZenecaNCT02032823Report a problem
- Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyCompletedPhase 3AstraZenecaNCT02184195Report a problem
- Platine, Avastin and OLAparib in 1st LineCompletedPhase 3Arcagy ResearchNCT02477644Report a problem
- Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)CompletedPhase 3AstraZenecaNCT02987543Report a problem
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 3AstraZenecaNCT03732820Report a problem
Tested on its own · 100 — no other medicine in its arm
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationRecruitingPhase 2National Cancer Institute (NCI)NCT04858334Against placebo after curative treatmentWritten as OlaparibReport a problem
- Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian CancerRecruitingPhase 1Daewoong Pharmaceutical Co. LTD.NCT07371104Generic tablets, bioequivalenceWritten as DWZ2501 (Olaparib 150mg)Report a problem
- Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene MutationsRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03786796Alone in kidney cancer with repair mutationsWritten as OlaparibReport a problem
- The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian CancerRecruitingPhase 1/2The Netherlands Cancer InstituteNCT07460180With cisplatin and hyperthermiaWritten as OlaparibReport a problem
- Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial CancerRecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT06712472Maintenance against observation after chemoradiationWritten as Olaparib (300 mg BID)Report a problem
- Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast CancerNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT05522491Alone in BRCA1-methylated breast cancerWritten as OlaparibReport a problem
- A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian CancerRecruitingPhase 1Boryung Pharmaceutical Co., LtdNCT07069335Generic tablets, bioequivalenceWritten as Olaparib 150 MGReport a problem
- Improving Peptide Receptor Radionuclide Therapy With PARP InhibitorsRecruitingPhase 1Erasmus Medical CenterNCT05870423With radionuclide therapy, doses foundWritten as olaparibReport a problem
- Olaparib in Patients With HRD Malignant MesotheliomaRecruitingPhase 2University of ChicagoNCT04515836Alone in HRD mesotheliomaWritten as OlaparibReport a problem
- Olaparib in PALB2 Advanced Pancreatic CancerRecruitingPhase 2Azienda Ospedaliero-Universitaria di ModenaNCT06078787Alone in PALB2 pancreatic cancerWritten as Olaparib 150 MGReport a problem
- Olaparib Maintenance Therapy in Metastatic Breast CancerRecruitingPhase 2National Taiwan University HospitalNCT05629429Maintenance against continued chemotherapy in breast cancerWritten as OlaparibReport a problem
- MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal CancerRecruitingPhase 2National Cancer Institute, NaplesNCT05233982Maintenance in BRCA wild-type ovarian cancerWritten as Olaparib Oral ProductReport a problem
- MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.RecruitingPhase 3National Cancer Institute, NaplesNCT05255471Beyond progression against platinum after secondary surgeryWritten as OlaparibReport a problem
- Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyCompletedPhase 3AstraZenecaNCT03534453Written as Olaparib 300mg tabletsReport a problem
- Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03212274Alone in IDH-mutant tumoursWritten as OlaparibReport a problem
- Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone MetastasisActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT03317392With radium-223 in prostate cancer, doses foundWritten as OlaparibReport a problem
- Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) MutationActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03953898Alone in leukaemia or myelodysplastic syndromeWritten as OlaparibReport a problem
- Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03598257Added to radiotherapy in inflammatory breast cancerWritten as OlaparibReport a problem
- Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic ChangesActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03375307Alone in bladder cancer with repair defectsWritten as OlaparibReport a problem
- Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker AnalysisActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03047135Alone in biochemically recurrent prostate cancerWritten as OlaparibReport a problem
Showing 20 of 100. See all 100 →
Tested with established drugs · 48 — they are given beside it
- Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell TumorsNot yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07850973With high-dose chemotherapy before stem cell transplantWritten as OlaparibReport a problem
- Pembro With Radiation With or Without OlaparibRecruitingPhase 2Zin W MyintNCT05568550Added to pembrolizumab and radiation in prostate cancerWritten as OlaparibReport a problem
- Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast CancerRecruitingPhase 4Wen-Ming CaoNCT07695259With trastuzumab and pertuzumab before surgery in older womenWritten as olaparib combined with trastuzumab and pertuzumabReport a problem
- Estradiol Plus Olaparib for Breast Cancer (PHOEBE)RecruitingPhase 1Mary D ChamberlinNCT05900895With estradiol in breast cancerWritten as OlaparibReport a problem
- Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectivenessRecruitingPhase 4Radboud University Medical CenterNCT05078671Boosted with cobicistat at a lower doseWritten as OlaparibReport a problem
- Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)RecruitingPhase 2Vall d'Hebron Institute of OncologyNCT06377267Added to bevacizumab in HRD ovarian cancerWritten as OlaparibReport a problem
- Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast CancerRecruitingPhase 2/3Cambridge University Hospitals NHS Foundation TrustNCT03150576Added to paclitaxel and carboplatin before triple-negative breast surgeryWritten as OlaparibReport a problem
- Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04394858Added to temozolomide in uterine leiomyosarcomaWritten as OlaparibReport a problem
- Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05554328Added to selumetinib in one armWritten as OlaparibReport a problem
- Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate CancerWithdrawnPhase 1Peter MacCallum Cancer Centre, AustraliaNCT07090369With 177Lu-PSMA and pembrolizumab in prostate cancerWritten as Olaparib (300 mg BID)Report a problem
- Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaActive, not recruitingPhase 2Washington University School of MedicineNCT04643379With pembrolizumab and carboplatin first-lineWritten as OlaparibReport a problem
- Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)CompletedPhase 3Merck Sharp & Dohme LLCNCT03976323Maintenance with pembrolizumab against pemetrexedWritten as OlaparibReport a problem
- Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)TerminatedPhase 2Merck Sharp & Dohme LLCNCT04191135With pembrolizumab against chemotherapy after inductionWritten as OlaparibReport a problem
- Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)Active, not recruitingPhase 2AstraZenecaNCT03775486Added to durvalumab as maintenance in lung cancerWritten as OlaparibReport a problem
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)Active, not recruitingPhase 3AstraZenecaNCT05171816Added to abiraterone first-line in prostate cancerWritten as olaparibReport a problem
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 3AstraZenecaNCT03732820On the US labelAdded to abiraterone first-line in prostate cancerWritten as olaparibReport a problem
- Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before SurgeryActive, not recruitingEarly Phase 1M.D. Anderson Cancer CenterNCT03943173Alone before chemotherapy in BRCA ovarian cancerWritten as OlaparibReport a problem
- A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)Active, not recruitingPhase 2AstraZenecaNCT03459846Added to durvalumab in bladder cancerWritten as OlaparibReport a problem
- Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell TransplantCompletedPhase 1M.D. Anderson Cancer CenterNCT03259503With high-dose chemotherapy before stem cell transplant in lymphomaWritten as OlaparibReport a problem
- A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube CancerActive, not recruitingPhase 2University Health Network, TorontoNCT02489006Before surgery and chemotherapy in ovarian cancerWritten as OlaparibReport a problem
Showing 20 of 48. See all 48 →
Tested in a combination · 175 — another drug in the study is under test too
- Carboplatin or Olaparib for BRcA Deficient Prostate CancerRecruitingPhase 2VA Office of Research and DevelopmentNCT04038502Against carboplatin, in sequence, in prostate cancerWritten as OlaparibReport a problem
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingPhase 3Merck Sharp & Dohme LLCNCT03486873Continued with pembrolizumab in an extension studyWritten as OlaparibReport a problem
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerRecruitingPhase 1National Cancer Institute (NCI)NCT04585958With trastuzumab deruxtecan in HER2-expressing cancersWritten as OlaparibReport a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377In gene-matched combination armsWritten as OlaparibReport a problem
- Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerRecruitingPhase 3NRG OncologyNCT06580314One or two years, with or without bevacizumabWritten as OlaparibReport a problem
- Pilot Trial for Treatment of Recurrent GlioblastomaEnrolling by invitationEarly Phase 1AHS Cancer Control AlbertaNCT05432518One of five drugs chosen for glioblastomaWritten as OlaparibReport a problem
- Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)RecruitingPhase 1/2National Cancer Institute (NCI)NCT04086485With Lu-177-DOTATATE, its dose foundWritten as OlaparibReport a problem
- WIRE - Novel Treatments in Renal Cell CancerRecruitingPhase 2CCTU- Cancer ThemeNCT03741426Alone or with new cediranib in kidney cancerWritten as OlaparibReport a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535One approved drug matched to tumour geneticsWritten as Olaparib (CLOSED TO ENROLLMENT)Report a problem
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690One window arm before pancreatic surgeryWritten as OlaparibReport a problem
- Molecularly Tailored Therapy in Advanced Pancreatic CancerNot yet recruitingPhase 2Herlev HospitalNCT07802418One matched option in tailored pancreatic cancer therapyReport a problem
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001As matched maintenance in a molecular studyWritten as Olaparib (300 mg BID)Report a problem
- Pembrolizumab, Olaparib, and Temozolomide for People With GliomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05188508With pembrolizumab and temozolomide in gliomaWritten as Olaparib and TemozolomideReport a problem
- An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibRecruitingPhase 2University of Colorado, DenverNCT05887609With mirvetuximab as maintenance in ovarian cancerWritten as OlaparibReport a problem
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135One arm of a paediatric precision platformWritten as OlaparibReport a problem
- Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/PembroRecruitingPhase 2University of Alabama at BirminghamNCT05952453With pembrolizumab as maintenance after neoadjuvant chemotherapyReport a problem
- An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian CancerRecruitingPhase 2Bai-Rong XiaNCT07667751With tislelizumab and sunitinib before ovarian surgeryReport a problem
- Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).RecruitingPhase 1/2Fundación de investigación HMNCT06607692With 177Lu-DOTATATE in children and adolescentsWritten as Olaparib; 177Lu-DOTATATEReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379With durvalumab in one I-SPY arm before breast surgeryWritten as Durvalumab plus OlaparibReport a problem
- Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)RecruitingPhase 2Australasian Gastro-Intestinal Trials GroupNCT06441747With durvalumab in gastrointestinal cancerWritten as OlaparibReport a problem
Showing 20 of 175. See all 175 →
Beside an established treatment under test · 21 — an approved drug, surgery or radiation is what the study tests
Tested with olaparib: Surgery or a procedure 10 · Radiation 3 · pembrolizumab 2 · durvalumab 2 · atezolizumab 1 · copanlisib hydrochloride 1 · sacituzumab govitecan 1 · abemaciclib 1
- Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerRecruitingPhase 1National Cancer Institute (NCI)NCT04633239In every armStandard partner; abemaciclib is addedWritten as OlaparibReport a problem
- WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCRecruitingPhase 2AGO Research GmbHNCT04644289In every armBoth cohorts take it; durvalumab is addedWritten as olaparibReport a problem
- Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)RecruitingPhase 2Swiss Cancer InstituteNCT06401980One standard option before darolutamide maintenanceReport a problem
- Metastasis-directed Therapy for Oligometastases of Breast CancerRecruitingPhase 3Tokyo Medical and Dental UniversityNCT06135714Part of systemic therapy; metastasis-directed therapy is addedReport a problem
- PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06245889In every armOne option after surgery in response-adapted therapyWritten as OlaparibReport a problem
- NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNot yet recruitingPhase 3Women's Cancer Study Group GmbHNCT07178730Optional after surgery in the standard armReport a problem
- Telmisartan in Prostate CancerRecruitingPhase 1Tyler J CurielNCT06168487One partner of telmisartan in some patientsReport a problem
- Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus ChemotherapyNot yet recruitingPhase 3The Netherlands Cancer InstituteNCT07486687Standard option in both arms; pembrolizumab is addedReport a problem
- CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate CancerNot yet recruitingPhase 2Fudan UniversityNCT07268794One systemic option before prostate surgeryReport a problem
- Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT06201234In every armBoth arms take it; elacestrant is addedWritten as Olaparib + ElacestrantReport a problem
- Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian CancerRecruitingPhase 2Shanghai Gynecologic Oncology GroupNCT05200260Standard maintenance option; surgery is studiedReport a problem
- Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based ChemotherapyRecruitingPhase 2Asan Medical CenterNCT05222971In every armBoth arms take it; durvalumab is addedWritten as OlaparibReport a problem
- Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate CancerRecruitingPhase 3Universitaire Ziekenhuizen KU LeuvenNCT06585007One standard option; metastasis-directed therapy is addedReport a problem
- Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast CancerRecruitingNot applicableCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06197581One PARP option; concurrent radiotherapy safety is studiedReport a problem
- Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT05406999One PARP option for some; intense hormone therapy is studiedReport a problem
- Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast CancerRecruitingNot applicableCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05345860Standard adjuvant option; a residual-disease strategy is studiedReport a problem
- Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02849496In every armBoth arms take it; atezolizumab is addedWritten as OlaparibReport a problem
- Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA MutationsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04548752In every armBoth arms take it; pembrolizumab is addedWritten as OlaparibReport a problem
- Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03842228In every armPartner while copanlisib's dose is foundWritten as OlaparibReport a problem
- Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment TrialWithdrawnPhase 2National Cancer Institute (NCI)NCT05967286In every armEvery arm takes it; alpelisib is added in someWritten as OlaparibReport a problem
Showing 20 of 21. See all 21 →
Beside a new treatment under test · 103 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with olaparib: cediranib 15 · ceralasertib 14 · tremelimumab 5 · capivasertib 5 · durvalumab 4 · adavosertib 4 · IT-101 3 · Iparomlimab/Tuvonralimab 3
- Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid TumorsNot yet recruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07933419Partner of new QLS5133 in one armReport a problem
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06797635Optional after surgery; new patritumab deruxtecan is studiedWritten as OlaparibReport a problem
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerRecruitingPhase 3ImunonNCT06915025In every armStandard maintenance option; new IMNN-001 is addedWritten as OlaparibReport a problem
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06966700In every armOptional after surgery; new sacituzumab tirumotecan is studiedWritten as OlaparibReport a problem
- Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast CancerRecruitingPhase 1Immunomic Therapeutics, Inc.NCT07652242Partner of new ITI-5000 vaccine in one partWritten as OlaparibReport a problem
- Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)RecruitingPhase 1/2Artios Pharma LtdNCT05898399Partner of new ART6043Written as OlaparibReport a problem
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesRecruitingPhase 2AbbVieNCT07024784Partner of new IMGN151 in one armWritten as OlaparibReport a problem
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04090567In every armPartner of new cediranib or ceralasertibWritten as OlaparibReport a problem
- Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT06298084Partner of new patritumab deruxtecanWritten as OlaparibReport a problem
- Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerRecruitingPhase 1Dana-Farber Cancer InstituteNCT06488378In every armPartner of new axatilimabWritten as OlaparibReport a problem
- Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP LossRecruitingPhase 1M.D. Anderson Cancer CenterNCT07382544In every armPartner of new navlimetostatWritten as OlaparibReport a problem
- Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerRecruitingPhase 1University of Colorado, DenverNCT06856499In every armPartner of new cirtuvivintWritten as OlaparibReport a problem
- A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate CancerNot yet recruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07641855In every armPartner of new BL-B01D1Written as OlaparibReport a problem
- Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid TumorsRecruitingPhase 1MOMA TherapeuticsNCT06545942Partner of new MOMA-313Written as OlaparibReport a problem
- Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian CancerNot yet recruitingPhase 1/2ARCAGY/ GINECO GROUPNCT07637851Standard maintenance option; new ubamatamab is addedReport a problem
- Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCRecruitingPhase 1/2Sichuan UniversityNCT06217757In every armPartner of new sugemalimabWritten as OlaparibReport a problem
- Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian CancerNot yet recruitingPhase 2/3Shanghai Municipal Hospital of Traditional Chinese MedicineNCT07550205One standard maintenance option; herbal granules are studiedReport a problem
- QLS5132 Combination Therapy in Advanced Solid TumorsNot yet recruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07453394Partner of new QLS5132 in one armWritten as QLS5132; Olaparib; BevacizumabReport a problem
- Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07454018Maintenance after new iparomlimab-tuvonralimab with chemotherapyReport a problem
- Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian CancerNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT07407452Partner of new QL1706 in one cohortWritten as OlaparibReport a problem
Showing 20 of 103. See all 103 →
Beside supportive care · 2 — a supportive treatment or test is studied
- Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance TherapyRecruitingNot applicableInstitut Claudius RegaudNCT06588322Given as first-line maintenance; blood DNA mutations are studiedReport a problem
- A Study of Serum Folate Levels in Patients Treated With OlaparibCompletedPhase 4Rush University Medical CenterNCT04024254Given as treatment; folate levels are studiedReport a problem
One option of several · 4 — a test or a strategy chooses among drugs
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedPhase 3Institut National de la Santé Et de la Recherche Médicale, FranceNCT03784014One of many targeted options chosen by sequencingWritten as Olaparib and DurvalumabReport a problem
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingPhase 2University of MiamiNCT05826964One switch option guided by blood DNAReport a problem
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524In every armOne of many drugs in individualised combinationsWritten as OlaparibReport a problem
- Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal CancerCompletedPhase 2Vejle HospitalNCT03251612One drug the sensitivity test can chooseReport a problem
As the comparator · 2 — what is tested is compared with olaparib
- Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian CancerNot yet recruitingPhase 2Shandong UniversityNCT07647653The comparator for fluzoparib with bevacizumabWritten as Olaparib+BevacizumabReport a problem
- A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular RelapseRecruitingPhase 3Prof. Wolfgang JanniNCT06643585One comparator option against trastuzumab deruxtecanReport a problem
Observed · 40 — patients on it are followed, or it is given outside a trial
- Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast CancerRecruitingHellenic Cooperative Oncology GroupNCT07066917One PARP inhibitor option observedReport a problem
- NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)RecruitingAstraZenecaNCT06890273With durvalumab, real-world use in endometrial cancerReport a problem
- Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing SurveillanceRecruitingAstraZenecaNCT06995833With or without durvalumab, post-marketing useReport a problem
- PROLONG (PRostateOLaparibONcombinationGcc) StudyNot yet recruitingAstraZenecaNCT07674121With hormone therapy in prostate cancer practiceWritten as Olaparib and Abiraterone CombinationReport a problem
- Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian CancerRecruitingHospices Civils de LyonNCT06572735Among PARP inhibitors, dose intensity in practiceReport a problem
- Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer PatientsRecruitingAzienda Ospedaliero-Universitaria di ModenaNCT07151911Among adjuvant breast cancer treatments in practiceWritten as abemaciclib, olaparib and endocrine therapyReport a problem
- Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world ScenarioRecruitingConsorzio OncotechNCT06836219With bevacizumab as maintenance, outcomes by HRDReport a problem
- Intensive Adjuvant Therapy for TNBC with BRCA Gene MutationEnrolling by invitationCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06405295Alone or with capecitabine after surgery, observedReport a problem
- Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate CancerRecruitingSanta Chiara HospitalNCT06783127Real-world use in prostate cancerWritten as OlaparibReport a problem
- Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.Enrolling by invitationFirst Affiliated Hospital Xi'an Jiaotong UniversityNCT04699006Real-world efficacy and side effects in ovarian cancerReport a problem
- PRostate Olaparib Real World Evidence StudyActive, not recruitingAstraZenecaNCT06031805Real-world use in prostate cancerReport a problem
- Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)Active, not recruitingAstraZenecaNCT06380738With abiraterone in prostate cancer practiceReport a problem
- 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)CompletedAstraZenecaNCT04553926Post-marketing surveillanceReport a problem
- Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese PatientsCompletedAstraZenecaNCT04560452Safety monitoring in Chinese practiceReport a problem
- Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)WithdrawnM.D. Anderson Cancer CenterNCT07475923One adjuvant option; blood DNA surveillance observedReport a problem
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated PatientsCompletedNovartis PharmaceuticalsNCT07477756One later treatment after lutetium-177 PSMAReport a problem
- LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)CompletedAstraZenecaNCT05677308Post-marketing surveillance in adjuvant breast cancerReport a problem
- LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)CompletedAstraZenecaNCT04889404Post-marketing surveillance in Japanese pancreatic cancerReport a problem
- Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UKCompletedAstraZenecaNCT04532645Real-world use in France, Italy and the UKWritten as OlaparibReport a problem
- Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World SettingCompletedAstraZenecaNCT06324734Safety in Chinese ovarian cancer practiceReport a problem
Showing 20 of 40. See all 40 →
As a tool · 5 — an imaging tracer or a test of drug response
- Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate CancerEnrolling by invitationPhase 1Brigham and Women's HospitalNCT04399876A microdose in an implanted deviceReport a problem
- Microdevice In Ovarian, Fallopian Tube, And Peritoneal CancerRecruitingPhase 1Brigham and Women's HospitalNCT04701645A microdose in an implanted deviceReport a problem
- Molecular Imaging of DNA Damage Response by [18F]-Olaparib PETNot yet recruitingPhase 1/2University Medical Center GroningenNCT06482307Labelled with fluorine-18 for PET imagingReport a problem
- A Dye for the Detection of Cancer of the Tongue and MouthActive, not recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT03085147An olaparib-based fluorescent dye for imagingWritten as OlaparibReport a problem
- Implantable Microdevice for TNBC - Pilot StudyWithdrawnPhase 1Dana-Farber Cancer InstituteNCT05774886A microdose released by an implanted deviceReport a problem
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted3
- Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyNov 16, 2026NCT03534453
- Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Nov 4, 2026NCT04753879
- Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaOct 27, 2026NCT04643379
Stopped1
Codes
What other systems call olaparib · ClinicalTrials.gg INT005326
- MeSH (NLM) C531550olaparibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) WOH1JD9AR8OLAPARIBConfirmed FDA, NLM, Wikidata
- RxNorm 1597582Confirmed FDA, Wikidata
- Wikidata Q7083106olaparibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71721OlaparibOne source FDA
- DrugBank DB09074One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531550 | olaparib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | WOH1JD9AR8 | OLAPARIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1597582 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7083106 | olaparib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71721 | Olaparib | One source FDA |
| DrugBank | DB09074 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.